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BACKGROUND: Given its hormonal activity, bisphenol S (BPS) as a substitute for bisphenol A (BPA) could actually increase the risk of endocrine dis-
ruption if its toxicokinetic (TK) properties, namely its oral availability and systemic persistency, were higher than those of BPA.
OBJECTIVES: The TK behavior of BPA and BPS was investigated by administering the two compounds by intravenous and oral routes in piglet, a
known valid model for investigating oral TK.
METHODS: Experiments were conducted in piglets to evaluate the kinetics of BPA, BPS, and their glucuronoconjugated metabolites in plasma and
urine after intravenous administration of BPA, BPS, and BPS glucuronide (BPSG) and gavage administration of BPA and BPS. A population semi-
physiologically based TK model describing the disposition of BPA and BPS and their glucuronides was built from these data to estimate the key TK
parameters that drive the internal exposure to active compounds.
RESULTS: The data indicated that almost all the BPS oral dose was absorbed and transported into the liver where only 41% of BPS was glucuroni-
dated, leading to a systemic bioavailability of 57.4%. In contrast, only 77% of the oral dose of BPA was absorbed and underwent an extensive first-
pass glucuronidation either in the gut (44%) or in the liver (53%), thus accounting for the low systemic bioavailability of BPA (0.50%). Due to the
higher systemic availability of BPS, in comparison with BPA, and its lower plasma clearance (3.5 times lower), the oral BPS systemic exposure was
on average about 250 times higher than for BPA for an equal oral molar dose of the two compounds.
CONCLUSION: Given the similar digestive tracts of pigs and humans, our results suggest that replacing BPA with BPS will likely lead to increased in-
ternal exposure to an endocrine-active compound that would be of concern for human health. https://doi.org/10.1289/EHP4599
Introduction
Due to concerns about its safety, the use of bisphenol A (BPA)
has been restricted, and structural analogs, especially bisphenol S
(BPS), have mainly replaced BPA in consumer products (ANSES
2013). As a result of its use to manufacture epoxy resins for inner
coating of food cans and packaging containers, the dominant
source of human exposure to BPS is considered to be contami-
nated food (Wu et al. 2018). The use of BPS as a color developer
of thermal papers (Wu et al. 2018) may also contribute to human
exposure through dermal and hand-to-mouth oral exposures. BPS
has thus been detected in 89.4% of urine samples from a repre-
sentative cohort of the U.S. population (n=868, Lehmler et al.
2018), with median urinary BPS concentrations of 0:37 lg=L.
Similar median levels of BPS exposure were reported in a study
conducted in pregnant women from Netherlands (0:36 lg=L;
Philips et al. 2018). The increased frequency of BPS detection in
urine samples collected between 2000 and 2014 (n=616) in U.S.
adult volunteers reflects the reality of substituting BPA with BPS
(Ye et al. 2015). The prevalence and level of human exposure
may also be increased by potential accumulation of BPS in the
environment resulting from its lower biodegradability, in compar-
ison with BPA, in seawater (Danzl et al. 2009).
In vitro studies have demonstrated the endocrine activity of
BPS, leading authors to raise the alert about its health hazard
potential and the risk of such substitution (Rochester and Bolden
2015). BPS, like BPA, has been shown to display estrogenic ac-
tivity via nuclear receptors, the potency of the effects depending
on the in vitro assay systems used and their related endpoints.
Hence, BPS showed less potent estrogen activities than BPA in a
human ovarian adenocarcinoma cell line (Rosenmai et al. 2014)
but was equipotent to BPA in human breast cancer MCF-7 cells
(Kuruto-Niwa et al. 2005). The ability of BPS to act as an estro-
gen receptor (ER) agonist may result from its binding to ER a
and b (Molina-Molina et al. 2013). The lower affinity of human
ERa andERb for BPS than for BPA, reported by the former
authors, is in agreement with its recently demonstrated lower
potent estrogenic activity via human ERa and b in comparison
with BPA (Kojima et al. 2019). Although these effects via nu-
clear receptors are observed at micromolar concentrations, some
studies have demonstrated that at picomolar (pM) concentrations,
BPS can activate nongenomic signaling pathways in pituitary
cells, as does BPA (Viñas and Watson 2013). BPS has also been
shown to decrease testosterone secretion ex vivo by mouse fetal
testes at a lower concentration than BPA (Eladak et al. 2015),
whereas, in vitro, the reduction of testosterone secretion by a
human adrenocortical carcinoma cell line required higher BPS
concentrations (Goldinger et al. 2015). Additionally, similar
effects of BPA and BPS have been reported on lipid accumula-
tion and the expression of adipogenic markers in human preadi-
pocytes (Boucher et al. 2014, 2016), the potency of the
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adipogenic effects of BPS on a preadipocyte murine line being
even greater than that of BPA (Ahmed and Atlas 2016).
Although limited in number, in vivo studies have also evidenced
similar effects of BPA and BPS treatments on mammary gland
development that was accelerated in mice prenatally exposed to
BPA or BPS (5 mg=kg, Tucker et al. 2018), a higher incidence of
mammary lesions being observed following prenatal exposure to
BPS at 0:5 mg=kg. The decrease of protein contents and testos-
terone concentrations of the rat testes after subchronic oral treat-
ments with 50 mg=kg of either BPA or BPS has been associated
with a reduction in the height of the epithelial tissues of seminif-
erous tubules (Ullah et al. 2018). Adverse reproductive outcomes
were also observed in female rats subcutaneously treated with ei-
ther BPA or BPS (5 and 50 mg=kg) during the neonatal period of
life, including delayed onset of puberty, a disrupted pattern of
estrous cyclicity, and detrimental effects on the ovarian develop-
ment and function (Ahsan et al. 2018).
The harmful consequences of the chemical substitution of
BPA with BPS for health may be further exacerbated if the toxi-
cokinetic (TK) properties of BPS increase its bioavailability and
enhance its persistence in the body, thereby resulting in higher
plasma concentrations of BPS than of BPA for the same external
exposure level. Indeed, the amounts of BPA that can reach the
target tissues and exert effects are dependent on plasma concen-
trations, these latter being related to the dose by a key TK param-
eter, namely the blood (plasma) clearance in addition to the
bioavailability. Bioavailability, which corresponds to the amount
of substance reaching the systemic circulation unchanged, is
determined by both the extent of gastrointestinal absorption and
of gut and hepatic first-pass elimination when exposure occurs
via the oral route. Due to the extensive first-pass glucuronidation
of orally administered BPA (Völkel et al. 2002) and its high
plasma clearance (Collet et al. 2015), the concentrations of un-
conjugated BPA in adult human plasma are predicted to be very
low (in the pM range, Gauderat et al. 2017; Teeguarden et al.
2013), the predominant form of circulating BPA being BPA glu-
curonide (BPAG) (Völkel et al. 2002).
Due to their lack of estrogenicity (Matthews et al. 2001;
Skledar et al. 2016), systemic exposure to bisphenol conjugated
metabolites is not taken into account for risk assessment pur-
poses. However, in vitro studies have suggested that BPAG may
exert biological activities similar to (Boucher et al. 2015) or dif-
ferent from those of the parent compound (Viñas et al. 2013).
Although it cannot be excluded that a possible back conversion
of BPAG to its unconjugated form might account for its effect on
adipocyte differentiation (Gayrard et al. 2015), the effect of
BPAG on some estrogenic signaling pathways in estrogen-
responsive prolactinoma cells, as opposed to that of BPA, sug-
gests that BPAG on its own may have the ability to interfere with
the actions of estrogens (Viñas et al. 2013). The fact that bisphe-
nol glucuronides cannot be considered as totally inactive raised
the need to evaluate systemic exposures to both the parent and its
glucuronidated metabolites.
Currently, the limited TK and metabolic data of BPS suggest
that although BPS, like BPA, is predominantly metabolized by
conjugation reactions (Le Fol et al. 2015; Skledar et al. 2016;
Zhou et al. 2014), the TK behavior of BPS may differ from that
of BPA. Indeed, Oh et al. (2018) showed that after oral dosing in
humans, the fraction of plasma BPS that was unconjugated (28%)
was much higher than the corresponding value for BPA (0.5%;
Thayer et al. 2015). Recently, these human biomonitoring data
have been used to calibrate a physiologically based toxicokinetic
model for BPS oral exposure (Karrer et al. 2018) and to predict
human serum concentration profiles of unconjugated BPS. The
modeled higher systemic exposure to BPS in comparison with
BPA has highlighted the need for experimental data to further
elucidate the TK behavior of BPS.
In that context, the objective of the present study was to develop
a data-driven semiphysiologically based TK model from data
obtained following intravenous administration of BPA, BPS, and
BPS glucuronide (BPSG) and gavage administration of BPA and
BPS in piglets, described as a relevant species for investigating oral
TK in humans (Kararli 1995). This approach, by enabling a compar-
ison of key TK parameters of BPA and BPS, namely plasma and re-
nal clearances, oral bioavailability, and glucuronidation, should
provide new insights for assessing the hazards of BPA substitution.
Methods
Animals
The animals used in this study were treated humanely and with
regard for the alleviation of suffering. All animal procedures were
carried out in accordance with accepted standards of humane ani-
mal care under agreement number 31-2011-142 from the French
Ministry of Agriculture. The protocol was approved by the re-
gional ethics committee (Midi-Pyrénées: protocol APAFiS
#12,367). The experiments were carried out on 27 piglets of Large
White breed (11 males and 16 females) originating from three
farms in the south of France (GIE Villefranche Grand Sud-
Villefranche de Rouergue, Marquié-Saint Ybars, and Calvignac-
St. Vincent d’Autejac), age 28 to 42 d and with body weights
(BW) between 8.75 and 27:82 kg.
The piglets were housed in a 12-m2 force-ventilated room and
had free access to drinking water. Piglets weighing less than
12 kg were fed a postweaning food (PrimeFeed; Vilofoss), the
piglets over 12 kg were fed with a flour-based growth food (PS2;
Solieval). The room was illuminated by artificial light on a 12-h
light/dark cycle, and the temperature was maintained at ∼ 25°C.
Experimental Design and Dosing
Table 1 summarizes the protocol of the experiments and the
plasma and urine datasets further considered for TK analyses. A
first experiment (Exp. 1) was performed in 8 male piglets age 42
d (20:8± 1:6 kg BW) to investigate oral BPA TK. At a 7-d inter-
val, piglets were administered BPA by intravenous route (IV)
and by gavage at respective doses of 21:9 lmol=kg (5 mg=kg),
and 438 lmol=kg (100 mg=kg), using a two-treatment, two-
sequence, two-period crossover design. BPA data obtained after
IV BPA administrations had already been used to evaluate human
BPA clearance using an allometric approach (Collet et al. 2015).
A second experiment (Exp. 2) designed to assess the elimina-
tion of BPA and BPAG in urine involved IV administration of
BPA at a dose of 21:9 lmol=kg in 3 male piglets age 38 d
(17:1± 0:46 kg BW). A third experiment (Exp. 3) was performed
in 6 female piglets age 28 d (10:9± 0:39 kg BW) to investigate
both BPS and BPSG TK after IV administration. Each piglet
received two successive IV administrations of BPS and BPSG at
respective doses of 20 lmol=kg (5 mg=kg) and 2:23 lmol=kg
(1 mg=kg), 72 h apart.
A fourth experiment (Exp. 4) was performed in 6 female pig-
lets age 28 d (10:6± 0:83 kg BW) to specifically evaluate the
extent of BPS absorption by oral route and to measure the sys-
temic bioavailability of BPS. The experiment was divided into
two periods separated by 72 h, during which the piglets were
administered BPS respectively at the dose of 20 lmol=kg
(5 mg=kg) by IV route and at a dose of 40 lmol=kg (10 mg=kg)
by orogastric gavage.
Finally, a fifth experiment (Exp. 5) was performed in 4 female
piglets age 28 d (9:4± 0:84 kg BW) to directly compare BPA
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and BPS disposition after IV and oral administration using a
cocktail approach. The experiment was divided into two periods
separated by 4 d during which the piglets received administra-
tions of both BPA and BPS by IV and oral routes at respective
doses of 20 lmol=kg (4:6 mg=kg for BPA and 5mg=kg for BPS)
and 200 lmol=kg (47:5 mg=kg for BPA and 50 mg=kg for BPS),
using a two-treatment, two-sequence, two-period crossover
design. Selection of the IV and oral BPA and BPS doses was
based on previous TK data to achieve plasma concentrations
greater than the limit of quantification (LOQ, 1 ng=ml) for about
8–10 h, i.e., sufficiently long to observe the terminal phase slope
and allow calculation of TK parameters (Collet et al. 2015;
Grandin et al. 2017).
Test Materials and Treatments
All materials for the preparation of solutions (including the
materials used for sampling, processing, and analysis) were
made of glass or BPA- and BPS-free plastic (polypropylene).
BPA (purity 99%) and BPS (purity >99%) were purchased
from Sigma-Aldrich. BPSG [(Bis(4-hydroxyphenyl) Sulfone
O-b-D-Glucuronide-Sodium Salt, purity 99.54%] was purchased
from Toronto Research Chemicals. Carboxymethylcellulose so-
dium salt and sucrose were obtained from Sigma-Aldrich.
For the IV administrations, BPA powder was dissolved in
ethanol–propylene glycol (1:49, vol:vol) at 50 mg=mL (Exp.1
and 2) and in ethanol–saline (1:2, vol:vol) at 23 mg=mL (Exp. 5).
BPS powder was dissolved in ethanol–saline (1:2, vol:vol) at
25 mg=ml (Exp. 3 and 4) and 50 mg=mL (Exp. 5), and BPSG
was dissolved in saline at 10 mg=mL.
For administrations by gavage, BPA powder was dissolved in
ethanol–corn oil (1:9, vol:vol) at 100 mg=mL (Exp. 1). BPS pow-
der was placed in a Luer-lock syringe, mixed with 2.5% (w/v) car-
boxymethylcellulose in 0:1 M phosphate buffer containing sucrose
(146 mg=mL) using a syringe adaptor, to yield a carboxymethylcel-
lulose gel containing 10 mg=ml of BPS (Exp. 4). For the cocktail
approach, BPA and BPS were both dissolved in ethanol–corn oil
(1:7, vol:vol) at 25 mg=mL (Exp. 5). The volume administered to
animals was adjusted to the individual BW recorded during the 2 d
precedingBPA,BPS andBPSGadministrations. The concentrations
of all dosing solutions were verified (Table S1) byAcquity ultra per-
formance liquid chromatography coupled to a Xevo triple quadru-
pole mass spectrometer (UPLC-MS/MS, Waters Corporation; see
the Sample Collection andAnalysis section).
BPA and BPS solutions were administered intravenously via
an indwelling catheter inserted into the auricular vein just before
the administrations and orally by gastric intubation. The animals
were fasted overnight prior to administration, had free access to
drinking water, and were given a standard meal 3 h postdose.
During the first 24 h of sampling, the piglets were housed indi-
vidually in stainless steel cages.
Sample Collection and Analysis
Serial jugular venous blood samples (1:5ml for Exp. 3–5 and
4ml for Exp.1 and 2) were taken before and after BPA, BPS, and
BPSG administrations. Total urine was collected before and after
each micturition (Exp. 1) or at different times regularly spanned
over 24 h after dosing (Exp. 2–5, Table 1). Blood samples were
collected in heparinized polypropylene tubes, immediately chilled
in ice and centrifuged for 10 min at 3,000× g at 4°C, and the su-
pernatant plasma was stored in polypropylene tubes at −20C until
assay. Total urine was filtered through a nylon mesh (250 lm) and
collected in glass containers and chilled in ice. The volume of each
urine sample and the sampling time were recorded. A urine sample
was immediately chilled in ice and centrifuged for 10 min at
3,000 × g at 4°C and stored at −20C until assayed.
Analytes were quantified by Acquity UPLC-MS/MS (Waters
Corporation). BPA, BPAG, BPS, and BPSG in plasma and urine
samples were simultaneously quantified, without resorting to a
hydrolysis step, according to the respective methods previously
described for BPA and BPAG (Lacroix et al. 2011) and BPS and
BPSG analyses (Grandin et al. 2017).
Briefly, samples (100 lL) were purified by protein precipitation
and quantified using BPA-13C12, BPS-d8, BPA-G 13C12 and BPS-G
d8 (Toronto Research Chemicals) as internal standards. They were
Table 1. Flowchart of the objectives, design and plasma and urine datasets in the experiments evaluating BPA and BPS toxicokinetics (TK).
Experiment Objectives What was done Data sets
1 Investigate BPA TK after IV and oral
administrations
21:9 lmol=kg IV and 438 lmol=kg oral
BPA dosing in 8 piglets at a 7-d
interval
- Serial jugular venous plasma samples obtained before
and at 30 min and 1, 2, 3, 4, 6, 8, 12, 15, 18, and 24 h
after BPA administration (and after 15 min for IV route)
- Total urine collected after each natural micturation until
24 h after BPA administration
2 Assess the elimination of BPA/BPAG
in urine
IV administration of BPA at a dose of
21:9 lmol=kg in 3 piglets
- Serial jugular venous plasma samples taken before and at
15min, 30 min, and 1, 2, 3, 4, 6, 8, 10, 12, and 24 h after
BPA administration
- Total urine collected at 3, 6, 9, 12, 15, 18, 21, 24, 28, 31,
35, 37, 45, and 48.5 h after BPA administration
3 Investigate BPS and BPSG TK after IV
BPS and BPSG administrations
IV administrations of BPS and BPSG at
the respective doses of 20 lmol=kg
and 2:23 lmol=kg in 6 piglets
- Serial jugular venous plasma samples taken before and at
15min, 30 min, and 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and
72 h after IV BPS and BPSG administrations
- Total urine collected at 3, 6, 9, 12, 21, and 24 h after
IVBPS and BPSG administrations
4 Evaluate the extent of BPS absorption
by oral route and measure the oral
bioavailability of BPS
20 lmol=kg IV BPS administration of
BPS followed by 40 lmol=kg BPS
administration by orogastric gavage in
6 piglets
- Serial jugular venous plasma samples at 15 min, 30 min,
and 1, 2, 3, 4, 6, 8, 10, 12, 24, 36, 48, and 72 h after BPS
administration by IV route and orogastric gavage
- Total urine collected at 3, 6, 9, 12, 21, and 24 h after
BPS administration by IV route and orogastric gavage
(and after 1 h only for IV route)
5 Compare BPA and BPS disposition
after IV and oral BPA administration
using a cocktail approach
20 lmol=kg IV administrations of both
BPA and BPS and 200 lmol=kg
administrations of both BPS and BPA
by orogastric gavage in 4 piglets
- Serial jugular venous plasma samples taken before and at
2, 5, 15, 30 min, and 1, 2, 3, 4, 6, 8, 12, 24, 34, 48, and
72h after BPA and BPS administrations
- Total urine collected at 3, 6, 9, 12, and 24 h after BPA
and BPS administrations
Note: BPA, Bisphenol A; BPAG, Bisphenol A glucuronide; BPS, Bisphenol S; BPSG, Bisphenol S glucuronide; IV, Intravenous; TK, Toxicokinetic.
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separated on a C18 column (with a water/acetonitrile gradient elu-
tion and detected in negative electrospray using the multiple reac-
tion monitoring mode. Chromatographic data were monitored by
Targetlynx® software (Waters Corporation). Blanks and quality-
control samples were used to monitor potential contamination dur-
ing analysis and the accuracy and precision of the method. The
mean intra- and interday coefficients of variation for three concen-
tration levels of BPA and BPAG and of BPS and BPSGwere lower
than 15%, respectively. The LOQ values for each molecule in
plasma and urine are given for each experiment in the Table S2.
TK Analyses
All TK analyses were performed using the Phoenix® NLME (ver-
sion 8.0; Pharsight Corporation). The plasma mass concentrations
were converted into molar concentrations before analysis. The
cumulated molar quantities of excreted BPA (BPAG, BPS,
BPSG) in urine were calculated by multiplying the molar concen-
trations of BPA (BPAG, BPS, BPSG) by the volume of urine at
each sampling time.
Noncompartmental Analysis
Plasma concentration–time profiles of BPA, BPAG, BPS, and
BPSG were first analyzed according to a noncompartmental
approach. The plasma analytes concentration–time data from indi-
vidual piglets were used to derive the maximum concentration
(Cmax), and the time to maximum concentration (Tmax). The area
under the plasma concentration–time curves from dosing time to
the time of the last measurable concentration (AUC0–tlast ) were cal-
culated using the linear trapezoidal rule (Equation 1).
AUC0–tlast =
Xtlast
0
Ci−1 +Ci
2
 
× ti − ti−1ð Þ (1)
where Ci is the concentration obtained at the time i (ti).
The area under the plasma concentration time curve from
t=0 to infinity (AUC0–inf ) was obtained using Equation 2.
AUC0–inf =AUC0–tlast +AUCtlast–inf (2)
where AUCtlast–inf is the area extrapolated from the last observation
to infinity, calculated according to Equation 3:
AUCtlast–inf =
Clast
kz
(3)
where Clast is the last observed quantifiable plasma concentration,
and kz is the slope of the terminal phase, as estimated by linear
regression using the best fit option of Phoenix®. AUCtlast–inf added
less than 6% of AUC0–tlast .
Plasma clearance (Cl) of BPA, BPS and BPSG were obtained
using Equation 4:
Cl=Dose=AUC0–inf (4)
where Dose is the IV administered BPA (BPS, BPSG) dose and
AUC0–inf calculated as previously described.
Apparent clearance of BPAG and BPSG (Cl_F) was esti-
mated after respective BPA and BPS IV administrations using
the Equation 5:
Cl F=Dose=AUC0–inf (5)
where Dose is the IV administered BPA (BPS) dose and
AUC0–inf calculated for BPAG (BPSG) as previously described.
Apparent clearances of BPA and BPAG (BPS and BPSG)
were also determined using Equation 5 after respective oral
administration of BPA and BPS.
TK Modeling
A nonlinear mixed effect (NLME) modeling approach was then
used to analyze data sets from the different experiments simultane-
ously and to provide robust estimates of the mean BPA and BPS
TK parameters and of their between-subject variability. The
NLME modeling approach is considered as a powerful tool for
applying meta-analysis to diverse TK studies (Li et al. 2015).
According to Food and Drug Administration guidance (FDA
1999), this TK approach can be used to analyze data from a variety
of unbalanced designs, i.e., study designs in which not all the indi-
viduals supply the same amount of information. The NLMEmodel
was therefore developed by combining the plasma and urinary data
sets from the five TK experiments carried out in piglets, except for
the urinary BPA concentration obtained after oral administration
of BPA. Indeed, after oral administration, the ratio of urinary
BPAG/BPA concentrations can be very large (>5,000) and even a
minimal post-sampling hydrolysis of BPAG, e.g., <1=1,000)
could be sufficient to severely bias the observed urinary BPA con-
centrations. The urinary BPS concentrations obtained after oral
administration of BPSwere kept becausefittingwas systematically
improved when considering these data. For plasma concentrations,
only concentrations above the LOQ were considered; indeed as
fewer than 10% of the plasma concentrations were below the LOQ,
they could be ignored without the risk of bias (Byon et al. 2008).
For urine the cumulative amount of BPA (BPS) and BPAG
(BPSG) excreted at different sampling times was computed, and
about 5 or 6 cumulated amounts, regularly spanned over the entire
elimination period, were considered for data fitting.
Different compartmental models and submodels were tested
and compared using the likelihood ratio test (LRT). The primary
parameters of the model, namely the volumes of distribution
(VBPA, VBPAG, VBPS, VBPSG) and the first-order rate constants
(Kij) and their associated precisions [standard error (SE)] were
estimated by minimizing an objective function value (OFV)
expressed as minus twice the log of the likelihood estimation
(−2LL).
The between-subject variability (BSV) of the parameters
was evaluated using the exponential model hparameter i =
htv parameter × expðgiÞ, where hparameter i is the parameter esti-
mated for the ith individual, htv parameter is the typical popula-
tion value of the parameter, and gi is the deviation associated
with the ith individual from the corresponding value of the pa-
rameter at the population level. The distribution of gi was
assumed to be normal with a mean of 0 and a variance x2. The
BSV was reported as a coefficient of variation (CV) in the origi-
nal scale CVð%Þ=100× ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiexp ðx2Þ− 1p . This random compo-
nent was estimated for those parameters for which the
shrinkage for g calculated as shrinkage=1− SDðEBEgÞx was
lower than 30%, SD (EBE) being the standard deviation of the
individual values of the Empirical Bayesian Estimates (EBE)
of g.
The residual variance was modeled using a combined additive
and proportional error model Cobsij =Cpredijð1+ e1ijÞ+ e2ij
where Cobsij and Cpredij are respectively the j
th observed and
predicted concentrations for the ith individual and e1ij and e2ij the
multiplicative and additive residual errors.
The bootstrap tool (20 replicates) was used to evaluate the
mean, median, SE, and coefficient of variation of the parameter
estimates. The predictive ability of the model was checked
graphically by plotting Visual Predictive Check plots to compare
the observed data with the selected quantiles (here 20th, 50th and
80th percentiles) of data simulated using the model and obtained
from 200–1,000 replicates from each animal based on the struc-
ture of the original data (i.e., dosing, timing and number of
samples).
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After exploration and comparison of different structural com-
partmental models, a 9-compartmental model based on the LRT,
the Akaike Information Criterion (AIC), and inspection of differ-
ent diagnostic plots (vide infra) was finally selected. For the LRT
test, the critical value of the v2 distribution considered for a given
nominal risk and a given number of degrees of freedom was
obtained using the Excel function CHISQ.INV.RT(). This model
(Figure 1) was selected to better describe and understand the fate
of BPA and BPS, i.e., to separately estimate absorption vs. bioa-
vailability and to qualify the processes of the first-pass effect
with a gut vs. a liver first-pass effect from the primary parameters
of the compartmental model.
The urinary clearance values for bisphenols (BPs), BPA, and
BPS, namely, CLBPs URINE, and their metabolites (BPs metabo-
lite), BPAG and BPSG, namely CLBPsmetabolite URINE, were esti-
mated from their respective population primary parameters using
Equation 6 and Equation 7.
CLBPs URINE =K30 ×VBPs (6)
where VBPs is the volume of the BPs central compartment, and
K30 is the BPs elimination rate constant from plasma to urine.
CLBPsmetabolite URINE =K50 ×VBPsmetabolite (7)
where VBPsmetabolite is the volume of central compartment of the
BPs metabolites, and K50 is the elimination rate constant of the
BPs metabolites from plasma to urine.
The fraction of BPA (BPS) that was absorbed by enterocytes
(Fabs) was estimated using Equation 8:
Fabs=
K12 +K110
K12 +K110 +K10
(8)
where K10 is the rate constant corresponding to the unabsorbed
BPs from the gastrointestinal tract, K12 is the rate constant of BPs
absorbed by the enterocytes passing directly into the portal blood,
and K110 is the rate constant of BPs absorbed by the enterocytes
locally subjected to glucuronidation.
The fraction of administered BPA (BPS) that was transformed
into BPAG (BPSG) by the gut wall (Fgutwall) was estimated by
Equation 9:
Fgutwall=
K110
K12 +K110 +K10
(9)
with K10, K12, and K110 as defined above.
The fraction of administered BPA (BPS) that was absorbed as
BPA (BPS) to reach the liver (Fliver) was estimated using
Equation 10:
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Figure 1. Schematic representation of the compartmental model. Note: The model included both a central and a peripheral compartment, respectively CP3 and CP4
for BPA (BPS) and CP5 and CP6 for BPAG (BPSG). The volumes of the BPA (BPS) and BPAG (BPSG) central compartments are respectively VBPA=BPS and
VBPAG=BPSG. The link between the two central compartments was modeled with a compartment (CP2) that should be viewed as the liver. For the oral route, BPA
(BPS) is administered in the gastrointestinal tract represented by CP1. A fraction of BPA (BPS) is absorbed by the enterocytes by passive diffusion to pass directly
into the portal blood via K12; a second fraction (K110) is absorbed by enterocytes and locally subjected to glucuronidation after which the formed BPAG (BPSG) is
absorbed into the systemic circulation and reaches CP5 via K105. A third fraction of the oral BPA (BPS) dose is directly eliminated by the digestive tract via K10. The
fraction of BPA passing into the portal blood via K12 is subjected to a hepatic first-pass effect which transforms part of the BPA (BPS) reaching the liver via K25 into
BPAG (BPSG) that passes into CP5. The fraction of absorbed BPA that is not hepatically transformed reaches the CP3 via K23. The exchanges between CP2 and
CP3 are bilateral, K32 being the rate constant between CP3 and CP2 and K23 the rate constant between CP2 and CP3. The urinary elimination of BPA (BPS) and
BPAG (BPSG) was modeled with a first-order rate constant designated K30 and K50 for BPA (BPS) and BPAG (BPSG), respectively. It was assumed that no phase-
two metabolite other than BPAG (BPSG) was formed. BPA, Bisphenol A; BPAG, Bisphenol A glucuronide; BPS, Bisphenol S; BPSG, Bisphenol S glucuronide;
CP: Compartment; IV, Intravenous; K10, Rate constant corresponding to the unabsorbed BPA (BPS) from the gastrointestinal tract; K12, Rate constant of BPA
(BPS) absorbed by the enterocytes passing directly into the portal blood; K23, K32, K34, and K43, Distribution rate constants between the plasma and the peripheral
compartments for BPA (BPS); K25, K56, and K65 Distribution rate constants between the plasma and the peripheral compartments for BPAG (BPSG); K30, BPA
(BPS) elimination rate constant from plasma to urine; K50, BPAG (BPSG) elimination rate constant from plasma to urine; K110, Rate constant of BPA (BPS)
absorbed by the enterocytes locally subjected to glucuronidation; K105, Rate constant of BPAG (BPSG) formed by the enterocytes absorbed into the systemic circu-
lation;VBPA=BPS Volume of the BPA (BPS) central compartment; VBPAG=BPSG, Volume of the BPAG (BPSG) central compartment.
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Fliver=
K12
K12 +K110 +K10
(10)
with K10, K12, and K110 as defined above.
The fraction of the administered BPA (BPS) dose
absorbed as BPA (BPS) and subsequently undergoing a he-
patic first-pass effect (Hepatic_firstpass) was estimated with
Equation 11:
Figure 2. Semilogarithmic plots of individual plasma concentrations relative to dose (lmol=Lper lmol=kg BW) vs. time (h) of BPA and BPAG after IV
(Figure 1A) and oral BPA dosing (Figure 1C) and of BPS and BPSG after IV (Figure 1B) and oral BPS dosing (Figure 1D) in piglets. BPA, Bisphenol A;
BPAG, Bisphenol A glucuronide; BPS, Bisphenol S; BPSG, Bisphenol S glucuronide; BW, Body Weight; IV, Intravenous.
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Hepatic firstpass=
K25
K25 +K23
(11)
where K23 is the distribution rate constant between the liver and
the plasma compartments for BPs, and K25 is the distribution rate
constant between the liver and the plasma compartments for BPs
metabolites.
The overall bioavailability of BPA (BPS), i.e., the percentage
of the BPA (BPS) dose that actually reached the systemic circula-
tion was estimated by combining equations 10 and 11 as
Equation 12.
Bioavailability=
K12
K12 +K110 +K10
× 1−
K25
K25 +K23
 
(12)
with K10, K12, K110, K23; K25 as defined above.
Statistical Analyses
All results are presented as mean±SD. ANOVA tests and
SYSTAT 12 (version 12; Systat Software, Inc.) were used to ana-
lyze the differences between the mean log-transformed BPA and
BPS TK parameter values, except those related to the highly dis-
similar BPA and BPS plasma concentrations obtained after oral
dosing (AUC0-tlast=dose, Cmax/dose, Cl_F).
Results
BPA and BPS were not detected in any of the control samples
obtained before the administrations, suggesting that little to no
sample contamination had occurred during sample collection,
processing, and assay.
Internal Exposure after IV and Oral Dosing
Figures 2A and 2B show the time course of individual plasma
concentrations relative to the dose of BPA and BPAG (Figure
2A) and of BPS and BPSG (Figure 2B) after IV dosing. BPA,
BPAG (Figure 2A), BPS, and BPSG plasma concentration–time
plots (Figure 2B) were obtained after both a single IV admini-
stration of BPA at 21:9 lmol=kg (Exp. 1 and 2, n=11) or BPS at
20 lmol=kg (Exp. 3 and 4, n=12) and simultaneous IV adminis-
trations of BPA and BPS at 20 lmol=kg (Exp. 5, n=4). Table 2
gives the values estimated by noncompartmental analysis for TK
parameters of BPA and BPAG vs. BPS and BPSG after the corre-
sponding IV BPA and BPS administrations. After IV administra-
tion to piglets, plasma BPA and BPS concentrations decreased
rapidly to reach values below the LOQ, beyond 12 h after admin-
istration. Mean BPS plasma clearance was about 3.5 times lower
than BPA clearance (0:95± 0:24 vs. 3:41±1:23 L= kg× h, p<
0:05). The time–concentration curves of BPAG and BPSG
plasma concentrations observed after IV BPA and BPS dosing
showed a comparable decay, with maximal plasma BPAG and
BPSG concentrations being obtained about 20 min after adminis-
tration and decreasing slowly to values below the LOQ of the
assay, beyond about 12–24 h and 8–12 h after the IV administra-
tions, respectively. The mean apparent clearance of BPSG was
of the same order as that of BPAG (0:41± 0:08 vs. 0:51±
0:12 L=kg× h). This value was close to the BPSG plasma clear-
ance determined after direct IV BPSG dosing (0:56± 0:12 L=
kg× h).
Figures 2C and 2D show the time course of individual plasma
concentrations relative to the dose of BPA and BPAG (Fig 2C)
and of BPS and BPSG (Fig 2D) after oral dosing. BPA, BPAG
(Figure 2C), BPS, and BPSG plasma concentration–time plots
(Figure 2D) were obtained after both a single oral administration
of BPA at 438 lmol=kg (Exp. 1, n=8) or BPS at 40 lmol=kg
(Exp. 4, n=6) and simultaneous oral administrations of BPA and
BPS at 200 lmol=kg (Exp. 5, n=4). Table 3 gives the values
estimated by noncompartmental analysis for TK parameters of
BPA and BPAG vs. BPS and BPSG after respective oral BPA
and BPS administrations.
After oral administrations, the BPA and BPS plasma concen-
trations increased to maximal values about 1 h and 30 min after
dosing, respectively. The average maximal BPS plasma concen-
trations were, in relation to the dose administered, more than 300
times higher than the maximal BPA values ranging from 173 to
951 nmol=L (43− 238 ng=ml) scaled for a nominal dose of
1 lmol=kg BW for BPS and from 0.059 to 5:75 nmol=L
(0:013− 1:31 ng=ml) scaled for a nominal dose of 1 lmol=kg
Table 2. Toxicokinetic parameters of BPA and BPS (mean±SD) estimated by noncompartmental analysis after BPA and BPS IV dosing.
Toxicokinetic parameter
BPA IV dosing (n=15) BPS IV dosing (n=16)
BPA BPAG BPS BPSG
Cmax/dose (lmol=L perlmol=kg BW) 0:48± 0:43 1:80± 0:85 2:12± 1:82* 2:55± 0:58
Tmax (h) NA 0:35± 0:34 NA 0:29± 0:19
AUC0-tlast=dose (lmol × h=L per lmol=kg) 0:34± 0:14 2:04± 0:58 1:11± 0:30
* 2:59± 0:77
Cl (L=kg× h) 3:41± 1:23 NA 0:95± 0:24* NA
Cl_F (L=kg× h) NA 0:51± 0:12 NA 0:41± 0:08
Note: The toxicokinetic parameters after IV dosing were estimated from datasets obtained after a single IV administration of BPA at 21:9 lmol=kg (Exp. 1–2, n=11), a single IV
administration of BPS at 20 lmol=kg (Exp. 3–4, n=12), and simultaneous IV administrations of BPA and BPS at the same dosage (Exp. 5, n=4). AUC0-tlast=dose Dose scaled area
under the plasma concentration–time curve from dosing time to the time of the last measurable plasma concentration;BPA, Bisphenol A; BPAG, Bisphenol A glucuronide; BPS,
Bisphenol S; BPSG, Bisphenol S glucuronide.; BW, Body weight; Cl, Clearance; Cl_F, Apparent clearance; Cmax/dose, Dose scaled maximal plasma concentration; IV, Intravenous;
NA, not applicable; Tmax, Time of Cmax. *Significantly different from mean values obtained with BPA (p<0:05, ANOVA test).
Table 3. Toxicokinetic parameters of BPA and BPS (mean±SD) estimated by non-compartmental analysis after BPA and BPS oral dosing.
Toxicokinetic parameter
BPA oral dosing (n=12) BPS oral dosing (n=10)
BPA BPAG BPS BPSG
Cmax/dose (lmol=L perlmol=kg BW) 0:0014± 0:0018 0:58± 0:34 0:51± 0:29 2:94± 4:78
Tmax (h) 0:95± 0:55 1:24± 1:07 0:53± 0:28 0:73± 0:30
AUClast/dose (lmol × h=Lper lmol=kg BW) 0:0024± 0:0027 1:75± 0:73 0:63± 0:29 2:87± 0:99
Cl_F (L=kg× h) 1270± 1250 0:65± 0:23 1:86± 0:73 0:38± 0:11
Note: The toxicokinetic parameters after oral dosing were estimated from data sets obtained after a single oral administration of BPA at 438 lmol=kg (Exp. 1, n=8), a single oral
administration of BPS at 40 lmol=kg (Exp. 3–4, n=6), and simultaneous oral administrations of BPA and BPS at 200 lmol=kg (Exp. 5, n=4). AUClast/dose, Dose scaled area under
the plasma concentration–time curve from dosing time to the time of the last measurable plasma concentration; BPA, Bisphenol A; BPAG, Bisphenol A glucuronide; BPS, Bisphenol S;
BPSG, Bisphenol S glucuronide; BW, Body weight; Cl_F, Apparent clearance; Cmax/dose, Dose scaled maximal plasma concentration; IV, Intravenous; Tmax, Time of Cmax.
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BW for BPA. The plasma concentrations of BPS remained above
the LOQ of the assay for 3 times longer than those of BPA. The
BPS systemic exposure after oral dosing was, on average, 262
times higher than that of BPA, the AUC0-tlast values relative to
dose ranging from 323 to 1,220 nmol × h=L (81− 305 ng× h=ml)
scaled for a nominal dose of 1 lmol=kg BW for BPS and from
0.23 to 9:21 nmol × h=L (0:053− 2:10 ng× h=ml) scaled for a
nominal dose of 1 lmol=kg BW for BPA. The time course of
BPAG and BPSG plasma concentrations observed after oral
administrations of BPA and BPS, respectively, did not differ
significantly.
Urinary Excretion of BPA and BPS
The cumulative urinary excretions of BPAG, BPS, and BPSG
that were recovered at fixed intervals over 24 h (Exp. 2–5) are
presented in Figure 3. By 24 h, the mean fractions ( ± SD) of the
BPA dose recovered in urine as BPAG was approximately two
times lower after oral BPA dosing (62:2± 15:8%, range: 49.5–
80.2%, n=4) than after IV BPA dosing (97:0± 27:6%, 63.1–
135.7%, n=7, Figure 3). The mean fractional urinary excretion
of BPS as BPSG was, respectively, 76:8±20:1% (36.3–107.9%,
n=16) and 86:5± 23:9% (65.5–126.8%, n=10) after IV and oral
BPS dosing. About half of the BPA and BPS doses were elimi-
nated 3 h after dosing. Two of the low BPSG recoveries (<70%)
were attributed to loss of urine at one collection time correspond-
ing to 6 h and 9 h post dosing.
Unconjugated BPA and BPS in urine represented, respec-
tively, 0:044±0:028% and 0:027± 0:0084% of the IV BPA and
BPS doses. The mean fraction of the IV BPSG dose recovered in
urine was 59:0± 9:96% (40.1–69.8%), 24 h post dosing.
TKModeling
For the present paper, the NLME modeling enabled several his-
torical information data sets to be used to generate a single set of
parameters (with their SE) for BPA and BPS. The estimated pri-
mary parameters (noted vector thetas), namely VBPA (VBPS),
VBPAG (VBPSG), and the 13 Kij of the model are reported with
their SE and their coefficient of variation (Tables S3 and S4). The
mean volume of the central compartment of BPA (1:0 L=kg) was
the highest in comparison with BPS (0:30 L=kg), BPSG
(0:14 L=kg), and BPAG (0:11 L=kg). Tables S5 and S6 report
the estimated variance matrix of g (x2) and BSV for the struc-
tural parameters of BPA and BPS TK model for which the
shrinkage for g was lower than 30% (K12, K23, K25, K30, K50,
VBPA, VBPAG, VBPS and VBPSG). The population predicted vs.
observed plasma concentrations of BPA and BPAG and of BPS
and BPSG (Figures S1 and S2) were evenly distributed around
the line of identity of the diagnostic plots, suggesting that these
data were appropriately described by the model. The goodness-
of-fit plots for corresponding individual predicted values sug-
gested the absence of any major bias in the random component of
the model. The population predicted vs. observed quantities of
BPA, BPAG, BPS, and BPSG excreted in urine (Figures S3A1–
S5A1 and Figures S3B1–S5B1) were distributed vertically, sug-
gesting that the model did not adequately predict these population
values, especially the very low quantities of BPA and BPS
excreted in urine (Figures S3A1–S5A1). Rather than discard
these urinary values, we kept them not only to ensure the trans-
parency of our results but also because the corresponding individ-
ual predicted values that were obtained by including a random
component in the structural model were reasonably well pre-
dicted by the model (Figures S3–S5). Figures S6–S9 show the
results of the Visual Predictive Check of the model for BPA and
BPS TK, respectively. For each figure except those related to the
very small quantities of BPA (Figure S7A) and BPS (Figure
S9A and B) excreted in the urine after BPA and BPS IV or oral
BPS dosing, the observed quantiles (20%, 50%, and 80%) are
reasonably well overlaid by the corresponding predictive check
quantiles.
Tables 4 and 5 show the population secondary parameters for
BPA/BPAG and BPS/BPSG, respectively, estimated from the
primary parameters of the model. Figure 4 compares the fates of
a same BPA and BPS dose given orally as predicted by the
model. The estimated fraction of the oral BPA dose absorbed by
the enterocytes was 76.6%, whereas BPS oral absorption was
near total. According to the model, about 34% of the BPA dose
(44% of the absorbed dose) was glucuronidated in the gut wall,
the near totality (99%) of the remaining fraction (40.3%, i.e., 53%
of the absorbed dose) being subjected to an hepatic first-pass
effect (39.9%). In contrast, the model predicted that nearly 100%
of the ingested BPS dose gained direct access to the liver, where
the estimated hepatic first-pass effect was only 41%. The lack of
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Figure 3. Cumulated urinary amounts of BPAG and BPSG in piglets after
respective BPA and BPS IV (•, mean+SD) and oral (▪, mean−SD) dosing.
BPAG urinary excretion was evaluated after both a single IV BPA adminis-
tration at 21:9 lmol=kg (Exp. 2, n=3) and simultaneous IV administrations
of BPA and BPS at 20 lmol=kg and after simultaneous oral administrations
of BPA and BPS at 200 lmol=kg (Exp. 5, n=4). BPSG urinary excretion
was evaluated after both a single IV BPS administration at 20 lmol=kg
(Exp. 3–4, n=12) and simultaneous IV administrations of BPA and BPS at
20 lmol=kg (Exp. 5, n=4) and after both a single oral BPS administration
at 40 lmol=kg (Exp. 4, n=6) and simultaneous oral administrations of BPA
and BPS at 200 lmol=kg (Exp. 5, n=4). Mean values were calculated at the
time periods where at least four values were available. The numbers above
or under the error bars indicate the number of animals for each time period.
BPA, Bisphenol A; BPAG, Bisphenol A glucuronide; BPS, Bisphenol S;
BPSG, Bisphenol S glucuronide; IV, Intravenous; Exp, Experiment; SD,
Standard deviation.
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a gut first-pass effect for BPS associated with a limited hepatic
first-pass effect resulted in a much higher oral bioavailable frac-
tion for BPS (57.4%) than for BPA (0.50%, Tables 4 and 5). The
renal clearance values of BPA (0:0020 L=kg× h) and BPS
(0:00035 L=kg× h) represented 0.06 and 0.037% of their respec-
tive plasma clearance values estimated by noncompartmental
analysis, whereas the renal clearance values of BPAG (0:277 L=
kg× h) and BPSG (0:243 L=kg× h) were close to their respective
apparent clearance values (Tables 4 and 5).
Discussion
The purpose of this study was to compare the oral TK of BPA
and its major alternative, BPS, and to quantify the key TK
mechanisms determining internal exposures. Our approach was
based on compartmental TK modeling of BPA, BPS, BPSG,
and BPAG in piglets, considered as a relevant species for trans-
lational research, because of their important anatomical and
physiological similarities with humans, with regard to gastroin-
testinal function.
By developing the TK model that merged different data sets
corresponding to the plasma and urinary concentrations of
BPA, BPS, and their glucuronides after IV and oral administra-
tion, we were able to estimate, using a comprehensive NLME
model, the relative contributions of the different pathways con-
trolling BPA and BPS plasma concentrations following oral ex-
posure. We estimated that the near totality (99%) of BPS was
absorbed after gavage administration, whereas the absorption
fraction represented only about 77% for BPA. According to the
model, BPS metabolism did not occur in the enterocytes,
whereas the gut was shown with the same model to contribute
to the first-pass glucuronidation of 44% of the BPA absorbed
fraction. Although only 41% of the BPS absorbed fraction was
glucuronidated in the liver, the near totality (99%) of BPA
unmetabolized in the enterocytes underwent an extensive he-
patic first-pass glucuronidation. The considerable extent of BPS
absorption associated with a lack of enterocyte first-pass metab-
olism and a moderate efficiency of hepatic first-pass BPS glu-
curonidation led to a systemic bioavailability of BPS that was
about 100 times higher than that of BPA (57.4 vs. 0.50%).
The plasma clearance of BPS estimated by noncompart-
mental analysis was about 3.5-fold lower than that of BPA
(0.95 vs. 3:41 L=kg× h), indicating that BPS is eliminated less
efficiently than BPA, as previously shown in sheep (Grandin
et al. 2017) and also explains its limited first-pass hepatic
effect. Considering these clearance values, it was deduced that
the renal clearance values of BPA (0.06%) and BPS (0.037%)
estimated from the model are negligible in comparison with
the metabolic hepatic clearance (higher than 99%). Assuming
that the plasma (or serum) and blood concentrations of BPS
are equal, the estimated hepatic extraction ratio of BPS, calcu-
lated from the ratio between the plasma clearance and the he-
patic blood flow (estimated at 2:6 L=kg× h in pigs from
allometric scaling; Boxenbaum 1980), was 0.37. The agree-
ment of this estimated value of the BPS fraction escaping pre-
systemic metabolism (63%) with BPS oral bioavailability
(57.4%) confirmed the predominant role of the liver for BPS
clearance. The closeness of the estimated renal clearance val-
ues of BPAG (0:28L=kg× h) and BPSG (0:25 L=kg× h) to the
respective apparent clearance values obtained by noncompart-
mental analysis (0.51 vs. 0:41 L=kg× h) and by BPSG plasma
clearance (0:56 L=kg× h) is in agreement with the hypothesis
that, as previously shown for BPA (Völkel et al. 2002), almost
all the administered BPS is metabolized into BPSG, glucuro-
noconjugates being mainly excreted in the urine.
The great extent of BPA and BPS absorption may be
explained by the relatively low molecular weights of BPA and
BPS (228.29 and 250.27) respectively and their moderate water
solubilities (LogP values of 3.3 and 1.65) respectively. The much
higher oral bioavailability of BPS in comparison with that of
BPA was rather unexpected due to the close chemical structure
of the compounds. Using a database for 309 drugs in humans,
Varma et al. (2010) showed that although lipophilicity favors
absorption, the fractions of drugs escaping gut-wall and hepatic
presystemic metabolism were decreased by lipophilicity, with
compounds having logP values greater than 3 demonstrating the
higher gut and hepatic extraction. This single physicochemical
descriptor is however insufficient to explain the highly different
extents of first-pass extraction of BPS in comparison with those
of BPA. All of the five examined BPA analogs, except BPS,
Table 4. Population secondary parameters of BPA/BPAG in pigs as obtained with a 9-compartment model.
Parameters Mean Median CV%
BPA fraction absorbed by the gastro-intestinal tract 0.765 0.766 7.84
Fraction of absorbed BPA undergoing a first-pass effect (gut and liver) 0.988 0.989 0.61
Fraction of administered BPA reaching the liver by the portal blood flow 0.405 0.403 27.13
Fraction of administered BPA glucuronidated by the gastro-intestinal tract 0.360 0.340 24.39
BPA renal clearance (L=kg× h) 0.0020 0.0020 23.35
BPAG renal clearance (L=kg× h) 0.277 0.279 14.12
BPA Bioavailability (%) 0.005 0.005 31.73
Note: The bootstrap procedure was used to estimate the mean, median, and precision (coefficient of variation, CV%) of parameter estimates. BPA: Bisphenol A; BPAG, Bisphenol A
glucuronide.
Table 5. Population secondary parameters of BPS/BPSG in pigs as obtained with a 9-compartment model.
Parameters Mean Median CV%
BPS fraction absorbed by the gastro-intestinal tract 0.986 0.989 0.956
Fraction of absorbed BPS undergoing a first-pass effect (liver) 0.435 0.408 17.412
Fraction of administered BPS reaching the liver by the portal blood flow 0.986 0.989 0.966
Fraction of administered BPS glucuronidated by the gastro-intestinal tract 0.00015 0.00014 66.823
BPS renal clearance (L=kg× h) 0.00035 0.00035 16.325
BPSG renal clearance (L=kg× h) 0.243 0.245 11.188
BPS Bioavailability (%) 0.557 0.574 12.935
Note: The bootstrap procedure was used to estimate the mean, median, and precision (coefficient of variation, CV%) of parameter estimates. BPS, Bisphenol S; BPSG, Bisphenol S
glucuronide.
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were predicted to be CYP2D6 substrates based on the in silico
structure activity relationship (Rosenmai et al. 2014), which sug-
gests that small changes in chemical structure could influence the
binding sites to enzymes and metabolism.
The difference in the extent of BPS and BPA glucuronidation,
both in the liver and the intestine as predicted by our model, is
consistent with the relative intrinsic clearance values of BPS vs.
BPA determined from the metabolic parameters (Vmax, Km)
obtained for intestinal and hepatic glucuronidation in humans
(Karrer et al. 2018). Hence, the liver and intestinal intrinsic clear-
ances of BPS computed from these parameters (0.325 and
0:0710 L=kg× h) are respectively 11 and 6 times lower than
those of BPA (3.67 and 0:433 L=kg× h). The lack of enterocyte
first-pass glucuronidation of BPS is also in agreement with the
low glucuronidation rate ratio of BPS between human intestine
and liver microsomes and the high activity of the hepatic
recombinant human UDP-glucuronosyltransferase (UGT) 1A9
towards BPS in comparison with the intestinal UGT1A10
(Gramec Skledar et al. 2015).
In piglets, the  100-fold higher amount available as circulat-
ing BPS in comparison with BPA after oral dosing, combined
with its 3.5 times lower plasma clearance, was responsible for the
 250 times higher systemic exposure to BPS resulting from oral
dosing, as reflected by the AUC values, whereas the systemic
exposures to BPAG and BPSG were very similar. The resulting
mean fraction of the total BPS in plasma (BPS plus BPSG) that is
BPS (23%) was much higher than the corresponding value for
BPA (0.16%). The former fractions are in the same order of mag-
nitude as those measured in humans after oral administration of
BPA or BPS on a cookie, i.e., 28% for BPS (Oh et al. 2018) and
0.56% for BPA (Thayer et al. 2015) which underscores the rele-
vance of our results for humans. A higher internal exposure to
BPS in comparison with BPA for equal external exposures could
explain the underestimation of BPS in vivo potency in the ovar-
iectomized rat uterotrophic assay from in vitro predictions based
on a bioassay of estrogenic activity (Conley et al. 2016).
Although in vivo effects may involve more complex mechanisms
than those targeted in vitro, the former study showed that BPS
was a more potent oral estrogenic compound in vivo than BPA
was, although it revealed a lower potential in vitro than BPA to
affect estrogenic and androgenic endocrine activity.
Currently, the use of BPS is not regulated and no tolerable
daily intake (TDI) has been defined for BPS despite its wide use
as substitute for BPA. If, in the current state of knowledge, the
estrogenic potency of BPS is considered to be similar to that of
BPA, and a correction factor of 250 is applied to the TDI of BPA
fixed temporarily at 4 lg=kg BW per day (EFSA CEF Panel
2015) to account for TK differences, the estimated safe level of
BPS would be 20 ng=kg BW per day. This value is not very dif-
ferent from the estimated median daily dietary intake of BPS, of
9:55 ng=kg BW/d (Liao and Kannan 2014), which suggests that
the margin of safety for BPS is very narrow.
Conclusion
Our study provides novel and critical information about BPS risk
assessment. The finding that orally ingested BPS may be highly
available as a circulating potentially endocrine-active compound
provides a key insight for assessing substitution of BPA with
BPS. Although the currently available toxicological data are con-
sidered insufficient for assessing the toxicity of BPA analogs, our
results emphasize the need for TK studies to screen and discard
those endocrine-active BPA substitutes to which human exposure
is potentially high.
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